- Home
- EVMN vs BBDC Comparison
EVMN vs BBDC Comparison
Compare EVMN & BBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVMN | BBDC |
|---|---|---|
| Founded | 2020 | 2006 |
| Country | United States | United States |
| Employees | 48 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Financial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.5M | 928.8M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | EVMN | BBDC |
|---|---|---|
| Price | $22.54 | $8.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $43.88 | $9.56 |
| AVG Volume (30 Days) | 279.0K | ★ 666.0K |
| Earning Date | 06-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 11.67% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $34.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.89 | $7.97 |
| 52 Week High | $33.20 | $9.92 |
Technical Indicators
Market Signals| Indicator | EVMN | BBDC |
|---|---|---|
| Relative Strength Index (RSI) | 40.64 | 45.95 |
| Support Level | $21.14 | $8.39 |
| Resistance Level | $25.50 | $9.08 |
| Average True Range (ATR) | 1.71 | 0.19 |
| MACD | -0.34 | -0.05 |
| Stochastic Oscillator | 9.01 | 12.50 |
Price Performance
Historical ComparisonAbout EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
About BBDC Barings BDC Inc.
Barings BDC Inc operates as a closed-end, non-diversified investment company and has elected to be treated as a business development company. The company's investment objective is to generate current income by investing directly in privately held middle-market companies to help these companies fund acquisitions, growth, or refinancing. It employs fundamental credit analysis and targets investments in businesses with low levels of cyclicality and operating risk relative to other businesses in this market segment. The holding size of each position will generally be dependent upon a number of factors including total facility size, pricing and structure, and the number of other lenders in the facility.